« Return to News | CROs/Service Providers

Certara acquires Simcyp, adding preclinical research capability

Thursday, March 1, 2012 11:00 AM

Certara, a provider of drug discovery and development software and scientific consulting services, will acquire U.K-based Simcyp, a research company providing a modeling and simulation platform for predicting the fate of drugs in virtual populations.

Simcyp will join the Certara portfolio and provide key, extensible technologies that support Certara’s translational science initiatives.

“The capabilities offered by Simcyp’s preclinical technologies, combined with our existing software products and scientific consulting services, will provide significant drug development advantages to our mutual and prospective clients,” said Jim Hopkins, CEO and president of Cerara. “This means broader capabilities to predict drug disposition as a function of molecular structure, and the ability to utilize a single unified suite of tools to facilitate preclinical and clinical PBPK and PKPD modeling and analysis.”

Clients from across the spectrum of drug discovery and development will have access to an expanded and integrated range of products and services, through the combination of Tripos, Simcyp and Pharsight science and functionality, according to Hopkins.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.